Focal Biosciences launched by PSI and Apollo Health Ventures
Business Wire - 11-Oct-2022Aims to treat age-related diseases using advanced cellular reprogramming technologies
Join the club for FREE to access the whole archive and other member benefits.
Venture capital firm investing in seed and early stage biotechnology companies
Apollo Health Ventures is an Early Stage Investment Firm interested in accelerating breakthrough scientific discoveries to the clinic by building life science companies around new therapeutic technologies. Apollo Ventures focuses on assets with the potential to treat, prevent, or even reverse age-related diseases such as Alzheimer's, Heart Disease, Sarcopenia, Frailty, and Cancer, with the ultimate goal of increasing healthy human lifespan. Apollo invests in early stage companies, works with scientists and entrepreneurs to create new ventures, and engages in hypothesis-driven company building.
Visit website: http://apollo.vc/
Details last updated 04-May-2019
Author, Chief Scientific Officer at Apollo Health, Professor and Founding President at Buck Institute for Age Research
Biotech Founder and Investor, Managing Partner at Apollo Health Ventures, Investment Partner at Hevolution Foundation
Co-Founder, Investment Director & Head of VentureLabs, Co-Founder at Apollo Health Ventures
Aims to treat age-related diseases using advanced cellular reprogramming technologies
Cleara’s novel FOXO4-based treatment approach-ability to eliminate biomarker-positive scarred cells
Founders are excited to find the impact when software intersects science
Invests in early stage companies that target root causes of age-related diseases
VCs are starting to recognise ageing as a problem with a massive business opportunity
Drugs will need to work better than the free alternative - calorie restriction
This therapy uses a modified FOXO4 to promote apoptosis in senescent cells